Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

ES-SCLC patients show limited benefit from 3L therapies, highlighting the need for novel treatments to improve outcomes. SCLC is aggressive, often diagnosed at an extensive stage, and treated with ...

A panelist discusses how early relapse and prognostic indicators shape second-line therapy selection and emerging treatment roles. A panelist discusses how early relapse within 6 months of ...

Prior to the NCCN guidelines release, 1.3% of patients in 2018 and 1.4% in 2019 underwent PNS screening; compared with 1.8% in 2020 and 1.7% in 2021, after publication of the updated SCLC guidelines.

Citing his advancing age and a need to plan for the future, Fred Luter Jr., the longtime senior pastor of Franklin Avenue Baptist Church in New Orleans, Louisiana, who served as the Southern Baptist ...

LAG-3 is identified as a potential biomarker for SCLC, aiding in patient stratification for ICI therapy. Higher LAG-3 expression in SCLC correlates with improved survival and increased immune activity ...

I-DXd showed a 46.2% intracranial cORR and 90.8% cDCR in ES-SCLC patients with brain metastases. Patients without prior brain radiotherapy had a higher intracranial cORR of 57.7%. The trial included ...